Examples include monotherapy and combination scenarios, including nivolumab therapy in NSCLC [21], HER2-negative breast cancer patients treated with anti-PD1, entinostat, and anti-CTLA-4 [22], or administration of a vaccine, anti-IL2, and ICIs in prostate cancer patients [23]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.